Organized by the Clinical Research Institute HUCH and the Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology.
Date: Thursday February 13, 2020
Location: Biomedicum Helsinki, lecture hall 1, Haartmaninkatu 8
Twitter: #HHD2020
PROGRAM
| 08:30 | Coffee | |
| 09:00 | Welcome and introduction | Ulla Wartiovaara-Kautto (@ullawk) Head of Hematology Department, Helsinki University Hospital Comprehensive Cancer Center |
| Session I: Updates in malignant hematology (chair: U. Wartiovaara-Kautto) | ||
| 09:10 | Management of lower risk MDS | Antonio Almeida Professor, Head of Department at Hospital da Luz, Lisbon and Head of the Hemato-Oncology Diagnostic Laboratory, Portuguese Institute of Oncology, Lisbon, Portugal |
| 09:50 |
AI/Machine learning in oncology/hematology |
Moritz Gerstung (@MoritzGerstung) |
| 10:40 | Coffee, exhibitions | |
| 11:00 | Molecular pathogenesis and therapy of myeloid malignancies |
Ross L. Levine (@rosslevinemd) |
| 12:00 | Lunch | |
|
|
||
|
Session II: Updates in stem cell transplantation (chair: Riitta Niittyvuopio) |
||
| 13:00 |
Welcome |
Riitta Niittyvuopio |
| 13:10 | New from the Finnish Stem Cell Registry | Tiina Linjama M.D., Specialist, Finnish Stem Cell Registry, Helsink |
| 13:40 | Current options in CMV management after allogeneic HSCT |
Per Ljungman |
| 14:20 | Patient-specific MRD markers predicting relapse after allogeneic stem cell transplantation for patients with MDS; Results from the Nordic study NMDSG14B | Magnus Tobiasson M.D., PhD, Department of Medicine, Hematology, Karolinska Institutet, Stockholm, Sweden |
| 15:00 | Closing words | Riitta Niittyvuopio Head of the transplantation unit, Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology |
Eeva Lind-Ekholm (eeva.lind-ekholm@hus.fi, 09-471 74581) 01.02.2020 mennessä. Mainitsethan samalla mahdollisesta erityisruokavaliosta.
Welcome! Tervetuloa!